If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
232
results.
Updated on
07/06/2025 [07:52:00]
Results 100 to 125 of 232
Absstract of: CN120078915A
本发明属于医学成像技术领域，具体涉及一种脑靶向APP@Dextran‑Fe3O4纳米颗粒及其制备方法和应用。本发明所提供的APP@Dextran‑Fe3O4纳米颗粒可通过非侵袭的静脉注射方式作用于脑内的β淀粉样蛋白受体，从而实现跨血脑屏障转运，并且在阿尔茨海默病患者的脑内具有更高的积累作用，尤其是在阿尔茨海默病主要的病变部位海马处异常累积，结合MPI成像高分辨率、高灵敏度的特点可实现阿尔茨海默病的诊断。同时病理分析发现APP@Dextran‑Fe3O4纳米颗粒具有抑制阿尔茨海默病脑内炎症反应，减少神经元细胞凋亡作用，对减缓阿尔茨海默病具有一定的益处。
Absstract of: CN120078743A
本发明提供了一种仿生小胶质细胞膜包覆的ZnS@BSA纳米颗粒及其制备方法和应用，属于生物纳米材料技术领域。本发明采用自组装方法，通过将醋酸锌和硫氢化钠与牛血清白蛋白(BSA)混合，合成了牛血清白蛋白的硫化锌纳米颗粒(ZnS@BSA)。由于BSA对金属离子具有亲和力以及延长半衰期的特性，可被广泛应用于纳米医学中。本发明利用挤压法制备了仿生小胶质细胞膜包覆的ZnS@BSA纳米颗粒(ZnS@BSA@MM)，ZnS@BSA@MM增强了牛血清白蛋白的硫化锌纳米颗粒在损伤部位的积累，并减少了血液循环中硫化氢的损失，促进了功能性神经元再生，抑制了神经瘢痕形成，并改善了SCI小鼠的运动功能恢复。
Absstract of: US2023139944A1
Provided herein, in some aspects, are agents, such as antibodies, chimeric antigen receptors, or RNA interference molecules that target the interaction between α3β1 integrin and α1 homotrimeric type I collagen. Aspects are directed to methods of treating cancer and fibroids comprising administering to a patient in need thereof an effective amount of an agent that disrupts the interaction between α3β1 integrin and α1 homotrimeric type I collagen. The methods can further include administering an effective amount of chemotherapy or immunotherapy to said patient.
Absstract of: CN119421871A
The present invention relates generally to the field of ionizable (also referred to as cationic) lipids, and particularly provides novel such lipids as represented by any chemical formula disclosed herein. The invention further provides methods for preparing such lipids and uses thereof, in particular in the preparation of nanoparticle compositions, more particularly nanoparticle compositions comprising nucleic acids. It further provides vaccine formulations and pharmaceutical formulations comprising nanoparticle compositions based on ionizable lipids disclosed herein.
Absstract of: WO2025108545A1
The invention provides sustained delivery of nucleic acids from hydrophobic/organic media, formulations and biomaterial depots.
Absstract of: CN119497629A
The present disclosure relates to compositions for expressing a constitutively active cyclic GMP-AMP synthase in a cell of a mammalian subject and their use for enhancing the immunogenicity of an mRNA vaccine. The mRNA may be encapsulated in a lipid nanoparticle (LNP) or may be complexed with a lipid (RNA-Lipoplex). The present disclosure also relates to compositions further comprising one or both of a lysophosphatidylcholine (LPC) compound and a pathogen-recognizing receptor agonist.
Absstract of: US2023381185A1
Described herein is a novel nanocomposite for oral administration for treatment of gastrointestinal disease, e.g., IBD, or injury. The nanocomposite contains nanoemulsion particles (NEs), loaded with an active therapeutic agent, that are then combined with a second component containing a self-assembling peptide(s) (SAP) or peptidomimetic(s) (optionally, the second component is in a powder form). Upon administration, when hydrated at slightly acidic or near-neutral pH, the system self-assembles into a hydrogel matrix enveloping NEs, which then adheres to, and more efficiently delivers, the active agent to the intestinal tract of a treated subject. The nanocomposite can be administered in a capsule dosage form that forms a depot in the stomach or post-stomach.
Absstract of: CN119487196A
The present disclosure provides, for example, therapeutic double stranded constructs (TDSC). In some embodiments, the TDSC comprises a double stranded DNA region, an upstream blocking end, and a downstream blocking end. In some embodiments, the TDSC comprises a chemically modified nucleotide. In some embodiments, the TDSC is resistant to endonuclease digestion and/or to immunosensor recognition, and supports expression of a heterologous load encoded in the TDSC.
Absstract of: CN119384272A
The present invention is in the field of RNA formulations, in particular freeze-drying of RNA. More particularly, the present invention relates to a lyophilized composition and a method of obtaining a lyophilized composition. Furthermore, the invention provides the use of the reconstitution composition according to the invention in human and/or veterinary medicine.
Absstract of: CN119384271A
A nanoparticle is provided comprising a composition comprising a polypeptide having a molecular weight of greater than 50,000 g/mol (e.g., an IgY antibody) wherein the composition is encapsulated in a material comprising a biocompatible bioerodible polymer. Also provided is a method of making these nanoparticles, as well as the use of the nanoparticles as therapeutic agents for the treatment of disease conditions.
Absstract of: WO2025111384A1
Compositions and methods for reducing complement activation by introducing one or more alterations into a complement factor B (CFB) polynucleotide in a cell. In particular embodiments, the invention of the disclosure features a base editor system (e.g., a fusion protein or complex comprising a programmable DNA binding protein, a nucleobase editor, and gRNA) for modifying a CFB polynucleotide, where the modification is associated with reduced expression, and/or reduced activity of the CFB polypeptide encoded by the polynucleotide.
Absstract of: WO2025111442A1
The present disclosure relates to lipids and compositions thereof. In various aspects of the invention, the compositions are lipid nanoparticle compositions used to deliver various DNA molecules and/or therapeutic agents to selected targets, such as cells for gene delivery, and/or to prevent or treat diseases or disorders in a subject in need thereof.
Absstract of: WO2025111454A1
Provided herein are compositions including ionizable lipids and lipid nanoparticles comprising the ionizable lipids. The ionizable lipids may have a general structure according to formula I: (I). Lipid nanoparticles generally include the ionizable lipid according to formula (I); a helper lipid; a sterol; and a PEGylated lipid conjugate. The ionizable lipids and lipid nanoparticles may be used to carrier cargo for a vaccine.
Absstract of: WO2025110775A1
The present invention relates to: a use of a gene delivery system as a drug carrier, the gene delivery system comprising metal nanoparticles and a double-helical nucleic acid molecule bound to the surface of the nanoparticles, in particular, a use of the delivery system for treating metabolic diseases; or a pharmaceutical composition for preventing or treating metabolic diseases, the pharmaceutical composition comprising the delivery system.
Absstract of: WO2025110773A1
The present invention relates to a gold nanoparticle carrier or a pharmaceutical composition for the prevention or treatment of cancer comprising the same, wherein the gold nanoparticle carrier includes gold nanoparticles, an antisense oligonucleotide (ASO) bound to the surface of the gold nanoparticles and binding specifically to a cancer-causing mutant gene, and an aptamer specific for a protein expressed by cancer cells.
Absstract of: WO2025110616A1
The present disclosure relates to a method for manufacturing a nanobubble-based drug carrier using focused ultrasound technology and a nanobubble-based drug carrier manufactured thereby and, more specifically, to a method for manufacturing a drug carrier containing a shell, with drugs and nanobubbles encapsulated inside the shell, using focused ultrasound technology, and a nanobubble-based drug carrier manufactured thereby.
Absstract of: WO2025110550A1
The present invention relates to a nucleic acid-based drug delivery platform. A complex according to the present invention has moderated toxicity and exhibits stable nucleic acid-binding ability due to osmotic activity. In addition, the complex promotes cell uptake of the nucleic acid supported on a polymer, and improves an endosomal release effect of the nucleic acid through degradation of nanoparticles in the cytoplasm. The complex according to the present invention has effects of maximizing gene expression of nucleic acids in a cell and contributing to maintaining the expression for a long time, and thus can be applied to various fields of immune activity, vaccine development, and the like.
Absstract of: WO2025110168A1
Problem To make available a silicate mineral having an average particle size larger than several hundred nm without containing impurities such as crystalline silica. Solution The content of crystalline silica and asbestos is 0.1 wt% or less in the silicate mineral of the present invention. The mineral preferably contains a carbonate and preferably has an average particle size of 100 nm or more. In addition, the mineral is suitably used in cosmetics, sanitary goods, pharmaceuticals, and foods. The silicate mineral is obtained by subjecting a natural silicate mineral to warm water or hot water treatment or hydrothermal reaction treatment at a pH of 9.4 or less.
Absstract of: WO2025110774A1
The present invention relates to a nanoparticle carrier and an antiviral composition comprising same, the nanoparticle carrier comprising: gold nanoparticles; antisense oligonucleotides (ASOs) that complementarily bind to conserved RNA sequences derived from a viral genome; and ribonuclease H (RNase H) that binds to the ASOs to induce the cleavage of mRNA. The nanoparticle carrier and the antiviral composition comprising same can reduce mRNA expression of a virus by RNase H, and in particular, can have the effect of treating infectious diseases caused by a virus.
Absstract of: WO2025109567A1
Provided herein are emulsion composition comprising a medium chain triglyceride (MCT), preferably tricaprilin. Also, described here are additional ingredients that make these emulsion compositions more suitable for oral intake, such as one or more emulsifiers, buffers such as phosphate buffers, as well as optionally glycerol and a sweetener and/or a flavoring agent. Described herein are methods of making and using these emulsions. The emulsions described may be used for oral administration of tricaprilin to treat and/or prevent various diseases or disorders.
Absstract of: WO2025108158A1
Provided are a celecoxib nanocrystal injection, a preparation method therefor, and use thereof, belonging to the field of pharmaceutical formulations. The provided celecoxib nanocrystal injection comprises celecoxib nanocrystals, a wetting agent, a stabilizer, and an osmotic pressure regulator. Moreover, the average particle diameter of the celecoxib nanocrystals is 100-500 nm. Optionally, the celecoxib nanocrystal injection further comprises a pH regulator and/or a lyoprotectant. After intravenous injection, the provided celecoxib nanocrystal injection can be rapidly dissolved in plasma, so that the application expectation of rapid onset of action in clinical acute pain management can be met. The celecoxib nanocrystal injection is prepared by adopting a combined technique of ball milling method and high-pressure homogenization. The ball milling method can process the micron-sized raw materials to the nanoscale, which can be further processed to a target particle diameter by high-pressure homogenization.
Absstract of: WO2025108355A1
A nucleic acid delivery carrier composition and use thereof. The composition comprises a cationic lipid, a helper phospholipid, cholesterol, and a PEG-conjugated lipid having a molar ratio of (30-50):(4-16):(31.5-63.5):(0.5-2.5); the helper phospholipid is one or a combination of two of DOPE and DSPC, and the cationic lipid is one or a combination of more structures selected from the following structures. The composition can wrap mRNA used for protein expression to treat related deficiency diseases, is efficient, and does not have toxic side effects.
Absstract of: WO2025108351A1
An ophthalmic cyclosporine nano-micelle drug, a preparation method therefor, and use thereof. The cyclosporine nano-micelle drug comprises: 0.1-10 parts by weight of a solubilizer for forming micelle particles, and 0.01-1 part by weight of cyclosporine loaded in the micelle particles. The solubilizer is a first solubilizer, or a combination of the first solubilizer and a second solubilizer.
Absstract of: WO2025107185A1
The present invention relates to the field of targeted therapy technology, and particularly, to a carrier, a targeted nanoparticle, a method for preparing same, and use thereof. The carrier disclosed in the present invention comprises tocilizumab grafted with a terminal carboxyl group-containing dye. The targeted nanoparticle comprises a carrier and a CO-release molecule. The carrier encapsulates the CO-release molecule to form a core-shell structure. In the targeted nanoparticle based on tocilizumab, the carrier is constructed by grafting the terminal carboxyl group-containing dye, and the carrier encapsulates the CO-release molecule. The carrier possesses a targeting effect, and the photothermal effect of the carrier can achieve the regulated CO release by NIR laser or targeted and controllable CO release under free radical stimulation, thereby achieving exogenous/endogenous dual-response release of CO. The present invention features good application prospects.
Nº publicación: CN120059980A 30/05/2025
Applicant:
大连理工大学
Absstract of: CN120059980A
本发明公开了一种EV衍生的工程化纳米膜囊泡的制备方法和应用，属于工程化纳米膜囊泡技术领域。本发明将来源于天然的膜组分和不同种类的脂质体通过膜融合的手段制备工程化的纳米囊泡载体，对生物活性分子RNA、DNA能够有效的装载和递送，有效发挥核酸纳米药物对细胞屏障的跨越功能，解决了传统磷脂类脂质体缺乏生物相容性和天然囊泡稳定性的弊端，该方法操作简单，处理样品量大，具有非常好的应用前景。
BOPI
Electronic site
